

## Special Issue

# Biomedical Imaging and Cancers

### Message from the Guest Editors

The discipline of radiology has been benefiting patients for over 100 years. A myriad of techniques are now available to image the human body both in terms of structure and function. The use of imaging in oncology has radically changed the patient treatment pathway, with the advent of radiomics and an increase in computing power; the use of artificial intelligence (AI) in biomedical imaging and cancers is now a real possibility. This Special Issue will encapsulate the uses of the latest imaging technologies for the purposes of diagnosis, staging, and treatment response in cancer. “Biomedical Imaging and Cancers” aims to cover new hybrid technology for acquisition and novel post-processing of imaging data to enhance and highlight biomarkers for detection of cancer, and the prediction and monitoring of responses to treatment. We are soliciting papers focusing on, but not limited to, new acquisition technology in imaging, novel methods of post processing, and machine learning and deep learning applied to imaging in cancer, biomarkers, and clinical trials.

---

### Guest Editors

Prof. Dr. Norman R. Williams

Surgical & Interventional Trials Unit (SITU), Division of Surgery & Interventional Science, University College London, 3rd Floor, Charles Bell House, 43–45 Foley St, London W1W 7JN, UK


Dr. Anna Barnes

Institute of Nuclear Medicine, University College London Hospitals NHS-Foundation Trust, 235 Euston Rd, London NW1 2BU, UK

---

### Deadline for manuscript submissions

closed (15 September 2020)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/43853](https://mdpi.com/si/43853)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).